Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Ian Walters"'
Autor:
Jijin Yang, Shi-Ming Lin, Christine Dela Cruz, Guoliang Shao, Ronnie T.P. Poon, Valerie Poulart, Ligong Lu, Lunan Yan, Xiaoping Yu, Joon-Hyeok Lee, Jean-Frédéric Blanc, Won Young Tak, Ian Walters, Richard S. Finn, Changping Wu, Tawesak Tanwandee, Jianhua Wang, Masatoshi Kudo, Guohong Han
Publikováno v:
Hepatology. 60:1697-1707
Transarterial chemoembolization (TACE) is the current standard of treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC). Brivanib, a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor si
Autor:
Josep M. Llovet, Riccardo Lencioni, Jean-Luc Raoul, Valérie Boige, Ho Yeong Lim, Charissa Chang, Masatoshi Kudo, Joong-Won Park, Ian Walters, Yoon-Koo Kang, Eric Assenat, Ferran Torres, José Ríos, Thomas Decaens, Robert Montal
Publikováno v:
Journal of Hepatology
Journal of Hepatology, 2017, 66 (6), pp.1166-1172. ⟨10.1016/j.jhep.2017.01.012⟩
Recercat. Dipósit de la Recerca de Catalunya
instname
Journal of Hepatology, Elsevier, 2017, 66 (6), pp.1166-1172. ⟨10.1016/j.jhep.2017.01.012⟩
Dipòsit Digital de la UB
Universidad de Barcelona
Journal of Hepatology, 2017, 66 (6), pp.1166-1172. ⟨10.1016/j.jhep.2017.01.012⟩
Recercat. Dipósit de la Recerca de Catalunya
instname
Journal of Hepatology, Elsevier, 2017, 66 (6), pp.1166-1172. ⟨10.1016/j.jhep.2017.01.012⟩
Dipòsit Digital de la UB
Universidad de Barcelona
Background & Aims: The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) was developed to overcome the limitations of standard RECIST criteria in response assessment of hepatocellular carcinoma (HCC). We aimed to investigate whether obj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dc51def091d1e0e8afb3bbd202650b8
https://hal.umontpellier.fr/hal-01790263
https://hal.umontpellier.fr/hal-01790263
Autor:
Jay Easaw, Derek J. Jonker, Ian Walters, Jenny Shannon, Jeremy Shapiro, Siobhan Ng, Lillian L. Siu, John Zalcberg, Christopher J. O'Callaghan, Andrew Strickland, Thierry Alcindor, Rami Kotb, Malcolm J. Moore, Heather Jane Au, Fabyolla El-Tahche, Sabe Sabesan, Mark Jeffery, Muhammad Salim, Jolie Ringash, Dongsheng Tu
Publikováno v:
Cancer. 120(2)
BACKGROUND The CO.20 trial randomized patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer to receive cetuximab (CET) plus brivanib alaninate (BRIV) or CET plus placebo (CET/placebo). METHODS Quality of life (QoL) was
Autor:
Chris Karapetis, Michael Jefford, Nadine M Magoski, Dongsheng Tu, Félix Couture, Michael B. Sawyer, Christopher J. O'Callaghan, Timothy J. Price, John Zalcberg, Derek J. Jonker, Ian Walters, Danielle Charpentier, Jeremy Shapiro, Jehan Siddiqui, John Simes, Jolie Ringash, Louise M. Nott, Malcolm J. Moore, Lillian L. Siu, Andrew Haydon, Winston Liauw
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(19)
Purpose The antiepidermal growth factor receptor monoclonal antibody cetuximab has improved survival in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal cancer. The addition of brivanib, a tyrosine kinase inhibitor target
Autor:
Eric Assenat, Ian Walters, Joong-Won Park, Josep M. Llovet, Masatoshi Kudo, Jean-Luc Raoul, Ferran Torres, H. Y. Lim, Charissa Chang, Eveline Boucher, Riccardo Lencioni, Valérie Boige, Yoon-Koo Kang, Thomas Decaens
Publikováno v:
Journal of Clinical Oncology. 33:4084-4084
4084 Background: mRECIST (modified Response Evaluation Criteria In Solid Tumors) was developed to overcome the limitations of standard RECIST in hepatocellular carcinoma (HCC) response assessment. Retrospective studies have correlated objective respo
Autor:
John Simes, Dongsheng Tu, Asif Shaikh, Lillian L. Siu, David Wyld, Warren Joubert, O'Callaghan. Christopher J., Malcolm J. Moore, Ian Walters, Craig Underhill, Penny Phillips, Benoit Samson, Timothy J. Price, Michelle F. Cronk, Antonino Bonaventura, Brian Peter Findlay, Jeremy Shapiro, Catherine Doyle, Derek J. Jonker, John Zalcberg
Publikováno v:
Journal of Clinical Oncology. 30:3572-3572
3572 Notice of Retraction: "Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts
Autor:
Andrew Haydon, Louise M. Nott, Timothy J. Price, John Simes, Michael B. Sawyer, Danielle Charpentier, Malcolm J. Moore, Derek J. Jonker, Jeremy Shapiro, Nadine M Magoski, Jehan Siddiqui, Christos S. Karapetis, Michael Jefford, Lillian L. Siu, John Zalcberg, Ian Walters, Christopher J. O'Callaghan, Winston Liauw, Félix Couture, Dongsheng Tu
Publikováno v:
Journal of Clinical Oncology. 30:3504-3504
3504 Background: The anti-EGFR monoclonal antibody CET has improved survival in pts with chemotherapy refractory, K-RAS WT mCRC. BRIV is a potent inhibitor of multiple receptor tyrosine kinases including both VEGFR and FGFR. The combination of CET an
Autor:
Ovidiu C. Trifan, Allen C. Chen, Ian Walters, Hervé Lena, Eugene Henry Paschold, Giorgio Cruciani, Glen Laird, Julien Mazieres
Publikováno v:
Journal of Clinical Oncology. 30:7584-7584
7584 Background: CT- 322 is a pegylated protein engineered from the tenth type III human fibronectin domain thatspecifically blocks VEGFR-2 signaling by all known ligands. This international randomized study assessed the efficacy and safety of PC + C
Autor:
Jean-Luc Raoul, Yee Chao, Laetitia Fartoux, D.-Y. Lin, Masatoshi Kudo, Y-K Kang, Rana Ezzeddine, Jordi Bruix, Morris Sherman, Won Young Tak, Eric Assenat, Ho Yeong Lim, Thomas Decaens, Joong-Won Park, Ian Walters, Charissa Chang, D. Liu, Valérie Boige, J.-F. Blanc, E. Boucher, Richard S. Finn, Philippe Mathurin, Ronnie T.P. Poon, Josep M. Llovet
Publikováno v:
Journal of Hepatology. 56:S549
Autor:
Andrew Strickland, Christopher J. O'Callaghan, Fabyolla El-Tahche, Jennifer Shannon, Derek J. Jonker, Heather-Jane Au, Lillian L. Siu, Jeremy Shapiro, Muhammad Salim, Ian Walters, Malcolm J. Moore, Rami Kotb, John Zalcberg, Mark Jeffery, Dongsheng Tu, Jacob C. Easaw, Jolie Ringash, Sabe Sabesan, Siobhan Ng, Thierry Alcindor
Publikováno v:
Journal of Clinical Oncology. 30:542-542
542 Background: The CO.20 trial randomized pts with K-RAS WT chemotherapy refractory mCRC to receive CET + BRIV (Arm A) or CET + placebo (Arm B). Although overall survival (primary endpoint) was not significantly improved (HR=0.88, p=0.12) in this he